Taglich Brothers Equities Analysts Raise Earnings Estimates for Nephros, Inc. (OTCMKTS:NEPH)

Share on StockTwits

Nephros, Inc. (OTCMKTS:NEPH) – Analysts at Taglich Brothers increased their Q3 2019 EPS estimates for shares of Nephros in a report released on Wednesday, October 16th. Taglich Brothers analyst H. Halpern now expects that the company will post earnings of ($0.12) per share for the quarter, up from their prior estimate of ($0.13). Taglich Brothers also issued estimates for Nephros’ FY2019 earnings at ($0.59) EPS, Q3 2020 earnings at $0.02 EPS, Q4 2020 earnings at ($0.02) EPS and FY2020 earnings at ($0.16) EPS.

NEPH has been the topic of several other reports. Zacks Investment Research upgraded shares of Nephros from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a report on Friday, October 18th. Maxim Group began coverage on shares of Nephros in a report on Friday, October 4th. They set a “buy” rating and a $16.00 target price on the stock.

Shares of NEPH stock opened at $10.00 on Monday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.86 and a current ratio of 2.56. The company has a market capitalization of $70.59 million, a P/E ratio of -18.52 and a beta of 0.85. The company’s 50 day moving average price is $8.46 and its two-hundred day moving average price is $4.08. Nephros has a 52 week low of $3.69 and a 52 week high of $11.35.

Nephros (OTCMKTS:NEPH) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.04. Nephros had a negative net margin of 49.93% and a negative return on equity of 56.37%. The business had revenue of $2.31 million for the quarter.

Nephros Company Profile

Nephros, Inc, a commercial stage medical device and commercial product company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems primarily in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.

See Also: What is dollar cost averaging (DCA)?

Earnings History and Estimates for Nephros (OTCMKTS:NEPH)

Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

$4.11 Billion in Sales Expected for Core-Mark Holding Company, Inc.  This Quarter
$4.11 Billion in Sales Expected for Core-Mark Holding Company, Inc. This Quarter
Saia  Stock Rating Lowered by BidaskClub
Saia Stock Rating Lowered by BidaskClub
Omnicell  Lifted to Buy at BidaskClub
Omnicell Lifted to Buy at BidaskClub
Medpace  Lifted to “Hold” at BidaskClub
Medpace Lifted to “Hold” at BidaskClub
Helen of Troy  Stock Rating Lowered by BidaskClub
Helen of Troy Stock Rating Lowered by BidaskClub
Corbus Pharmaceuticals  Lifted to Sell at BidaskClub
Corbus Pharmaceuticals Lifted to Sell at BidaskClub


 
© 2006-2019 Zolmax.